======= CDKN1B =======
== Gene Information ==
* **Official Symbol**: CDKN1B
* **Official Name**: cyclin dependent kinase inhibitor 1B
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=1027|1027]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P46527|P46527]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=CDKN1B&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CDKN1B|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/600778|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014].
* **UniProt Summary**: Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA (PubMed:28666995). Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A- CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. {ECO:0000269|PubMed:10831586, ECO:0000269|PubMed:12244301, ECO:0000269|PubMed:16782892, ECO:0000269|PubMed:17254966, ECO:0000269|PubMed:19075005, ECO:0000269|PubMed:28666995}.
|CDI|
|negative regulation of cardiac muscle tissue regeneration|
|transforming growth factor beta receptor, cytoplasmic mediator activity|
|regulation of cardiac muscle tissue regeneration|
|regulation of lens fiber cell differentiation|
|negative regulation of epithelial cell proliferation involved in prostate gland development|
|autophagic cell death|
|regulation of epithelial cell proliferation involved in prostate gland development|
|cyclin-dependent protein serine/threonine kinase inhibitor activity|
|Cul4A-RING E3 ubiquitin ligase complex|
|cellular response to lithium ion|
|mitotic cell cycle arrest|
|negative regulation of vascular smooth muscle cell proliferation|
|regulation of exit from mitosis|
|response to lithium ion|
|protein kinase inhibitor activity|
|negative regulation of cyclin-dependent protein serine/threonine kinase activity|
|positive regulation of microtubule polymerization|
|negative regulation of cyclin-dependent protein kinase activity|
|cyclin binding|
|positive regulation of cyclin-dependent protein serine/threonine kinase activity|
|positive regulation of microtubule polymerization or depolymerization|
|positive regulation of cyclin-dependent protein kinase activity|
|Hsp70 protein binding|
|negative regulation of smooth muscle cell proliferation|
|regulation of vascular smooth muscle cell proliferation|
|regulation of microtubule polymerization|
|negative regulation of reproductive process|
|DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest|
|signal transduction involved in mitotic DNA integrity checkpoint|
|intracellular signal transduction involved in G1 DNA damage checkpoint|
|signal transduction involved in mitotic cell cycle checkpoint|
|signal transduction involved in mitotic G1 DNA damage checkpoint|
|signal transduction involved in mitotic DNA damage checkpoint|
|mitotic G1/S transition checkpoint|
|mitotic G1 DNA damage checkpoint|
|response to cadmium ion|
|G1 DNA damage checkpoint|
|negative regulation of wound healing|
|signal transduction involved in DNA damage checkpoint|
|signal transduction involved in DNA integrity checkpoint|
|signal transduction involved in cell cycle checkpoint|
|DNA damage response, signal transduction by p53 class mediator|
|regulation of microtubule polymerization or depolymerization|
|positive regulation of cell cycle arrest|
|negative regulation of response to wounding|
|protein phosphatase binding|
|mitotic DNA damage checkpoint|
|regulation of cyclin-dependent protein serine/threonine kinase activity|
|negative regulation of G1/S transition of mitotic cell cycle|
|regulation of cyclin-dependent protein kinase activity|
|chaperone binding|
|signal transduction in response to DNA damage|
|mitotic DNA integrity checkpoint|
|negative regulation of developmental growth|
|negative regulation of cell cycle G1/S phase transition|
|regulation of cell cycle arrest|
|response to amino acid|
|cellular response to antibiotic|
|G1/S transition of mitotic cell cycle|
|cell cycle G1/S phase transition|
|signal transduction by p53 class mediator|
|negative regulation of epithelial cell proliferation|
|Notch signaling pathway|
|positive regulation of protein polymerization|
|DNA damage checkpoint|
|negative regulation of protein serine/threonine kinase activity|
|regulation of smooth muscle cell proliferation|
|response to estradiol|
|response to glucose|
|regulation of wound healing|
|regulation of epithelial cell differentiation|
|response to hexose|
|DNA integrity checkpoint|
|sensory perception of sound|
|cell cycle arrest|
|response to monosaccharide|
|regulation of G1/S transition of mitotic cell cycle|
|placenta development|
|mitotic cell cycle checkpoint|
|regulation of reproductive process|
|regulation of cell cycle G1/S phase transition|
|sensory perception of mechanical stimulus|
|regulation of response to wounding|
|regulation of mitotic nuclear division|
|potassium ion transport|
|response to carbohydrate|
|negative regulation of cell growth|
|regulation of microtubule cytoskeleton organization|
|regulation of nuclear division|
|cellular response to metal ion|
|inner ear development|
|cell cycle checkpoint|
|positive regulation of supramolecular fiber organization|
|negative regulation of mitotic cell cycle phase transition|
|positive regulation of protein catabolic process|
|cellular response to inorganic substance|
|positive regulation of cytoskeleton organization|
|ear development|
|regulation of microtubule-based process|
|regulation of protein polymerization|
|negative regulation of protein kinase activity|
|negative regulation of cell cycle phase transition|
|negative regulation of growth|
|negative regulation of kinase activity|
|positive regulation of protein complex assembly|
|protein-containing complex binding|
|mitotic cell cycle phase transition|
|endosome|
|negative regulation of transferase activity|
|cell cycle phase transition|
|positive regulation of cell cycle process|
|response to antibiotic|
|negative regulation of mitotic cell cycle|
|negative regulation of cellular component movement|
|negative regulation of cell cycle process|
|regulation of developmental growth|
|regulation of epithelial cell proliferation|
|positive regulation of protein serine/threonine kinase activity|
|response to hypoxia|
|response to acid chemical|
|regulation of supramolecular fiber organization|
|response to decreased oxygen levels|
|negative regulation of response to external stimulus|
|response to metal ion|
|positive regulation of cell cycle|
|response to oxygen levels|
|regulation of protein catabolic process|
|response to peptide hormone|
|monovalent inorganic cation transport|
|negative regulation of protein phosphorylation|
|regulation of mitotic cell cycle phase transition|
|regulation of cell growth|
|reproductive structure development|
|reproductive system development|
|positive regulation of catabolic process|
|negative regulation of phosphorylation|
|regulation of cell cycle phase transition|
|regulation of protein complex assembly|
|protein kinase binding|
|response to peptide|
|regulation of protein serine/threonine kinase activity|
|positive regulation of cellular component biogenesis|
|heart development|
|response to inorganic substance|
|positive regulation of protein kinase activity|
|regulation of cytoskeleton organization|
|cellular response to organic cyclic compound|
|sensory organ development|
|negative regulation of phosphate metabolic process|
|negative regulation of phosphorus metabolic process|
|negative regulation of cell cycle|
|positive regulation of kinase activity|
|negative regulation of protein modification process|
|mitotic cell cycle process|
|positive regulation of organelle organization|
|regulation of mitotic cell cycle|
|metal ion transport|
|positive regulation of transferase activity|
|developmental process involved in reproduction|
|regulation of growth|
|negative regulation of cell population proliferation|
|mitotic cell cycle|
|intracellular membrane-bounded organelle|
|positive regulation of cell death|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|negative regulation of catalytic activity|
|regulation of protein kinase activity|
|cation transport|
|response to lipid|
|circulatory system development|
|regulation of kinase activity|
|negative regulation of apoptotic process|
|negative regulation of programmed cell death|
|response to hormone|
|positive regulation of cell population proliferation|
|response to organic cyclic compound|
|negative regulation of developmental process|
|regulation of cellular component biogenesis|
|sensory perception|
|regulation of transferase activity|
|negative regulation of cell death|
|regulation of catabolic process|
|regulation of cellular component movement|
|cell cycle process|
|response to organonitrogen compound|
|positive regulation of protein phosphorylation|
|response to drug|
|negative regulation of cellular protein metabolic process|
|programmed cell death|
|positive regulation of phosphorylation|
|response to nitrogen compound|
|cell death|
|regulation of response to external stimulus|
|negative regulation of protein metabolic process|
|positive regulation of phosphorus metabolic process|
|positive regulation of phosphate metabolic process|
|negative regulation of molecular function|
|response to abiotic stimulus|
|regulation of cell cycle|
|negative regulation of transcription, DNA-templated|
|negative regulation of multicellular organismal process|
|positive regulation of cellular component organization|
|positive regulation of protein modification process|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|regulation of organelle organization|
|negative regulation of RNA metabolic process|
|cell cycle|
|ion transport|
|nervous system process|
|negative regulation of cellular macromolecule biosynthetic process|
|reproductive process|
|reproduction|
|positive regulation of catalytic activity|
|negative regulation of nucleobase-containing compound metabolic process|
|regulation of protein phosphorylation|
|negative regulation of macromolecule biosynthetic process|
|response to endogenous stimulus|
|regulation of response to stress|
|negative regulation of cellular biosynthetic process|
|regulation of apoptotic process|
|negative regulation of biosynthetic process|
|response to oxygen-containing compound|
|regulation of programmed cell death|
|regulation of phosphorylation|
|positive regulation of cellular protein metabolic process|
|regulation of cell population proliferation|
|negative regulation of response to stimulus|
|regulation of cell death|
|intracellular signal transduction|
|cellular response to stress|
|positive regulation of protein metabolic process|
|negative regulation of gene expression|
|positive regulation of molecular function|
|regulation of phosphate metabolic process|
|regulation of phosphorus metabolic process|
|regulation of cell differentiation|
|regulation of protein modification process|
|system process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp375|Lenalidomide 20μM R07 exp375]]|-1.8|
|[[:results:exp358|FK-506 5μM R07 exp358]]|-1.79|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|1.71|
|[[:results:exp510|Nicotine 3000μM R08 exp510]]|1.78|
|[[:results:exp352|Dexamethasone 0.006 to 0.015μM on day4 R07 exp352]]|1.86|
|[[:results:exp493|IL-3 9ng/ml R08 exp493]]|2.13|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|2.44|
|[[:results:exp504|MK2206 4μM R08 exp504]]|2.52|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|3.51|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 18802
* **Expression level (log2 read counts)**: 5.86
{{:chemogenomics:nalm6 dist.png?nolink |}}